Feasibility of an online cognitive rehabilitation programme in patients with a haematological malignancy undergoing autologous stem cell transplantation.
chemotherapy
cognitive impairment
cognitive rehabilitation
haematological malignancy
survivorship
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
25
11
2020
received:
30
08
2020
accepted:
30
12
2020
pubmed:
20
1
2021
medline:
26
10
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
Chemotherapy-related cognitive impairment (CRCI) is a known adverse event that can impact cancer survivors, resulting in long-standing effect on quality of life and activities of daily living. Currently, there is limited knowledge regarding the aetiology and therapy for CRCI. Although CRCI following autologous stem cell transplantation (AuSCT) is emerging as a potentially significant concern for patients with underlying haematological malignancies, it is an area that requires further research. This pilot study aimed to assess (i) the prevalence of CRCI in patients with haematological malignancies both pre-AuSCT and post-AuSCT and (ii) the feasibility of a cognitive rehabilitation programme (CRP) in survivorship care post-AuSCT. Over a 12-month period, consecutive patients planned for AuSCT were approached for the study. Enrolled patients were administered a 9-week course of CRP, commencing day 40 ± 5 post-AuSCT. Participants were evaluated using a neuropsychological tool and validated questionnaires at baseline, pre-CRP (day 40 ± 5 post-AuSCT), post-CRP and 6 months post-CRP. Thirty-two patients were enrolled. The mean age was 59 years (SD = 11.5), 23 (72%) were male and 18 (56%) had multiple myeloma. Participants reported high satisfaction using the CRP, and most devoted significant amount of time as requested. While there appeared to be a low incidence of significant CRCI in our patient population, the incorporation of CRP in survivorship care appeared to be feasible. A larger randomised study examining the efficacy of CRP should be further explored.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy-related cognitive impairment (CRCI) is a known adverse event that can impact cancer survivors, resulting in long-standing effect on quality of life and activities of daily living. Currently, there is limited knowledge regarding the aetiology and therapy for CRCI. Although CRCI following autologous stem cell transplantation (AuSCT) is emerging as a potentially significant concern for patients with underlying haematological malignancies, it is an area that requires further research.
AIMS
OBJECTIVE
This pilot study aimed to assess (i) the prevalence of CRCI in patients with haematological malignancies both pre-AuSCT and post-AuSCT and (ii) the feasibility of a cognitive rehabilitation programme (CRP) in survivorship care post-AuSCT.
METHODS
METHODS
Over a 12-month period, consecutive patients planned for AuSCT were approached for the study. Enrolled patients were administered a 9-week course of CRP, commencing day 40 ± 5 post-AuSCT. Participants were evaluated using a neuropsychological tool and validated questionnaires at baseline, pre-CRP (day 40 ± 5 post-AuSCT), post-CRP and 6 months post-CRP.
RESULTS
RESULTS
Thirty-two patients were enrolled. The mean age was 59 years (SD = 11.5), 23 (72%) were male and 18 (56%) had multiple myeloma. Participants reported high satisfaction using the CRP, and most devoted significant amount of time as requested.
CONCLUSIONS
CONCLUSIONS
While there appeared to be a low incidence of significant CRCI in our patient population, the incorporation of CRP in survivorship care appeared to be feasible. A larger randomised study examining the efficacy of CRP should be further explored.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1665-1672Subventions
Organisme : Department of Health and Human Services, State Government of Victoria
Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-93.
Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003; 9: 967-82.
Poppelreuter M, Weis J, Külz A, Tucha O, Lange K, Bartsch H. Cognitive dysfunction and subjective complaints of cancer patients: a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004; 40: 43-9.
Fan HGM, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1-and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23: 8025-32.
Brezden CB, Phillips K-A, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-701.
Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, Van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-5.
Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007; 25: 2455-63.
Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 2008; 18: 121-31.
Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J 2008; 14: 396-400.
Potrata B, Cavet J, Blair S, Howe T, Molassiotis A. ‘Like a sieve’: an exploratory study on cognitive impairments in patients with multiple myeloma. Eur J Cancer Care 2010; 19: 721-8.
Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander A et al. Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 39: 789-99.
Votruba K, Hoodin F, Giordani B, Kentor R, Couriel D, Kitko C. Prospective computerized monitoring of cognitive functioning before and after blood and marrow transplantation. Bone Marrow Transplant 2017; 52: 1215-17.
Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer 2013; 119: 4188-95.
Hahn T, Paplham P, Austin-Ketch T, Zhang Y, Grimmer J, Burns M et al. Ascertainment of unmet needs and participation in health maintenance and screening of adult hematopoietic cell transplantation survivors followed in a formal survivorship program. Biol Blood Marrow Transplant 2017; 23: 1968-73.
Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol 2011; 29: 2397-404.
Syrjala KL, Dikmen S, Langer SL, Roth-Roemer S, Abrams JR. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood 2004; 104: 3386-92.
Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol 2009; 24: 689-98.
Jacobs SR, Small BJ, Booth-Jones M, Jacobsen PB, Fields KK. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer 2007; 110: 1560-7.
Ahles TA, Tope DM, Furstenberg C, Hann D, Mills L. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1457-62.
Andrykowski MA, Schmitt FA, Gregg ME, Brady MI, Lamb DG, Henslee-Downey PJ. Neuropsychologic impairment in adult bone marrow transplant candidates. Cancer 1992; 70: 2288-97.
Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11: 6-15.
Von AD, Russell KM, Storniolo AM, Carpenter JS, eds. Cognitive dysfunction and its relationship to quality of life in breast cancer survivors. Oncol Nurs Forum 2009; 36: 326-36.
Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007; 16: 772-7.
Ferguson RJ, McDonald BC, Rocque MA, Furstenberg CT, Horrigan S, Ahles TA et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012; 21: 176-86.
Von Ah D, Carpenter JS, Saykin A, Monahan P, Wu J, Yu M et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2012; 135: 799-809.
Sohlberg MM, Mateer CA. Cognitive Rehabilitation: An Integrative Neuropsychological Approach. New York: Guilford Publications; 2017.
Kesler S, Hosseini SH, Heckler C, Janelsins M, Palesh O, Mustian K et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 2013; 13: 299-306.
King S, Green HJ. Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol 2015; 5: 72.
Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol 2016; 35: 217-25.
Lin J, Ebert D, Lehr D, Berking M, Baumeister H. Internet based cognitive behavioral interventions: state of the art and implementation possibilities in rehabilitation. Die Rehabil 2013; 52: 155-63.
Cuijpers P, Van Straten A, Andersson G. Internet-administered cognitive behavior therapy for health problems: a systematic review. J Behav Med 2008; 31: 169-77.
Hedman E, Ljótsson B, Lindefors N. Cognitive behavior therapy via the internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 745-64.
Jocham HR, Dassen T, Widdershoven G, Halfens RJ. Quality-of-life assessment in a palliative care setting in Germany: an outcome evaluation. Int J Palliat Nurs 2009; 15: 338-45.
Jacobs SR, Jacobsen PB, Booth-Jones M, Wagner LI, Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoetic stem cell transplant patients. J Pain Symptom Manage 2007; 33: 13-23.
Victorson D, Barocas J, Song J, Cella D. Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization. Qual Life Res 2008; 17: 1137-46.
Vodermaier A, Linden W, Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst 2009; 101: 1464-88.
Al kalaldeh MT, Shosha GM. The application of the perceived stress scale in health studies. An analysis of literature. Int J Acad Res 2012; 4: 45-50.
Athilingam P, Edwards JD, Valdes EG, Ji M, Guglin M. Computerized auditory cognitive training to improve cognition and functional outcomes in patients with heart failure: results of a pilot study. Heart Lung 2015; 44: 120-8.
Chen C-X, Mao R-H, Li S-X, Zhao Y-N, Zhang M. Effect of visual training on cognitive function in stroke patients. Int J Nurs Sci 2015; 2: 329-33.